611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Functional Interaction Seen for Dietary Carbohydrates With AMDTaking Opioids Before Knee Surgery Could Raise Pain LaterATS: First Abx Rx Doesn't Work for ~25% of Pneumonia CasesActemra Approved for Certain Blood Vessel InflammationStudy Casts Doubt on Need for Statins in the 'Healthy Old'First-Try Antibiotics Now Fail in 1 in 4 Adult Pneumonia CasesOvercrowded ERs Risky for Some Seriously Ill PatientsHigh Vitamin K1 Intake Linked to Reduced Cataract RiskPoverty Could Make Lupus Even WorseCDC: Crypto Outbreaks Linked to Pools Have Doubled Since 2014Could Cancer Drug Gleevec Help With Severe Asthma?Zika Mosquito Can Transmit Other Viruses, TooFDA OKs Kalydeco for Additional Mutations in Cystic FibrosisKalydeco Approval Widened for More Types of Cystic FibrosisAnother Step Toward Ebola ProtectionThe Water's Not Fine: U.S. Pool-Linked Infection Doubles in 2 YearsJust 2 Weeks on the Couch Can Trigger Body's DeclineGene Therapy Might Someday Mend Badly Broken Bones'Healthy Obese' May Be a MythNo Evidence Steroids Benefit Symptomatic Knee OsteoarthritisHeart Attack Risk Spikes After Respiratory Infection, Study FindsFor Inflamed Pancreas, Eating Right Away May Be Best MedicineFindings Support More Targeted Approach to Cholesterol ScreensHouston, You Have a 'Superbug'Forget Steroid Shots for Long-Term Relief of Arthritic KneesFDA Approves New Device to Treat Esophageal AtresiaMany U.S. Travelers Skip Measles Shots, Despite Infection RiskMany Under 40 May Not Need Regular Cholesterol Checks: StudyNew Device Approved for Esophageal Birth DefectACP: Recommendations Updated for Low Bone Density TreatmentMosquito-Borne Illnesses May Not Be Limited to TropicsArthroscopy for Degenerative Knees Deemed Seldom EffectiveBioengineered Intraabdominal Endocrine Pancreas FeasibleAllergies Getting Worse? Blame Climate ChangeA 2nd Life for Risky Kidney Transplants?Blood Vessel-Clearing Procedure Riskier on Weekends: StudyMultidrug-Resistant TB Set to Increase Through 2040Coming This Summer: More Ticks and a Deadly New Tick-Borne DiseaseAdherence to DASH Diet May Help Lower Occurrence of Gout'Groundbreaking Strides' Made in Zika Vaccine ResearchNew Guidelines Say No to Most 'Keyhole' Knee SurgeriesWhat Harms the Young Heart Also Hurts the Brain LaterHope for 1st Drug Against Lymphedema, a Cancer ComplicationHealth Tip: Getting Over a Stomach VirusEat This Diet to Lower Your Odds for Painful GoutPCSK9 Linked to New-Onset Diabetes After Renal TransplantZika Risk May Be Lower Than Thought for Some Pregnant WomenDDW: Autonomously-Controlled 'Capsule Robot' Can Explore ColonInternet-Based Vestibular Rehab Beneficial for DizzinessTestosterone May Protect Men From Allergic Asthma
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

1st Drug for Tardive Dyskinesia Approved

HealthDay News
by -- Scott Roberts
Updated: Apr 12th 2017

WEDNESDAY, April 12, 2017 (HealthDay News) -- Ingrezza (valbenazine), the first drug to treat adults with the neurological disorder tardive dyskinesia, has been approved by the U.S. Food and Drug Administration.

The disorder is characterized by repetitive involuntary movements, usually of the jaw, lips and tongue. Affected people may stick out the tongue, smack the lips, involuntarily move the arms and legs, and have trouble breathing, the FDA said in a news release.

The disorder may be a side effect of older antipsychotic medications to treat conditions such as schizophrenia, depression or bipolar disorder. It's not known why some users of these medications develop tardive dyskinesia, while others don't, the agency said.

"Tardive dyskinesia can be disabling and can further stigmatize patients with mental illness," said Dr. Mitchell Mathis, director of the FDA's Division of Psychiatry Products. "Approving the first drug for the treatment of tardive dyskinesia is an important advance for patients suffering with this condition."

Ingrezza's effectiveness was established in a clinical study of 224 people that compared the drug to a placebo. Potential side effects included sleepiness and abnormal heartbeat. Anyone taking Ingrezza should not drive or use heavy machinery until the effects of the drug on the person are known, the FDA warned.

Approval of Ingrezza was given to Neurocrine Biosciences, based in San Diego.

More information

To learn more, visit the FDA.